Glenmark

Glenmark is a leading global pharmaceutical company founded with the vision of becoming a premier integrated, research-based, global player in the pharmaceutical industry. The company is involved in developing, manufacturing, and marketing a wide range of products internationally. Its branded generics business caters to developed markets, particularly in the United States and Western Europe, while its Active Pharmaceutical Ingredients (API) business serves over 65 countries, including both the United States and several EU nations, South America, and India. With a robust infrastructure comprising 10 manufacturing facilities and 4 R&D centres, Glenmark operates across 50 countries, employing approximately 15,000 individuals and maintaining a commercial presence in 80 countries. Glenmark has established itself as one of the top 100 biopharma companies globally, demonstrating significant growth in the last five years, with an annual turnover of about USD 700 million. The company has received numerous accolades, including the title of "Best company in emerging markets" and the company with the "Best overall pipeline" at the SCRIP Awards 2011.

Services include:
- Anatomical Therapeutic Chemical (ATC) Classification
- Drug Delivery Devices & Systems
- Research and Development (R&D)
- Manufacturing of Generic and Branded Pharmaceuticals
- Contract Manufacturing (CMO/CDMO)
- Active Pharmaceutical Ingredients (APIs)

Glenmark remains committed to innovation and excellence in the pharmaceutical sector, solidifying its position as a key player in the global market. For more information, visit glenmarkpharma.com.